ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2023
New-Onset Diabetes after an Obesity-Related Cancer Diagnosis and Survival Outcomes in the Women's Health Initiative.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
Aladdin ShadyabHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California.ORCID 0000-0002-9693-0522
Scott A SummersDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-4919-0592
William L HollandDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-9950-1435
Thunder JaliliDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-7821-2287
Mary C PlaydonDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-6082-0447
University of Utah · USAlbert Einstein College of Medicine · USDartmouth College · USFred Hutch Cancer Center · USHuman Longevity (United States) · USIndiana University Bloomington · USSulaiman Al Rajhi Colleges · SAThe Lundquist Institute · USUniversity of Arizona · US
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Women's Health Initiative Cancer Survivor CohortUM1CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., CAAN, BETTE J · 2013 to 2018
$12.1M
New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
Life and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor CohortU01CA173642 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L., PASKETT, ELECTRA D. · 2019 to 2023
$7.5M
Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7M
The Role of Ceramides in Skeletal MuscleR01DK115824 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2018 to 2021
$2.6M
The Role of Ceramides in the Intestinal Stem CellR01DK131609 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI EDGAR, BRUCE ALEXANDER, SUMMERS, SCOTT A · 2021 to 2025
$2.5M
The Role of Ceramides in the Pancreatic Beta CellR01DK130296 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLLAND, WILLIAM L, SUMMERS, SCOTT A · 2022 to 2025
$2.2M
Targeting a Ceramide Double Bond to Treat Cardiometabolic DisordersR01DK122001 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2019 to 2022
$1.9M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
Metabolic health phenotype, accelerated aging and obesity-related cancer risk and mortalityK00CA264400 · NCI · DARTMOUTH COLLEGE · PI KARRA, PRASOONA · 2022 to 2024
$300k
Metabolic Obesity Phenotypes and Obesity-related Cancer SurvivalF30CA278348 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Maci Winn · 2023 to 2026
backgroundIndividuals diagnosed with an obesity-related cancer (ORC survivors) are at an elevated risk of incident diabetes compared with cancer-free individuals, but whether this confers survival disadvantage is unknown.
methodsWe assessed the rate of incident diabetes in ORC survivors and evaluated the association of incident diabetes with all-cause and cancer-specific mortality among females with ORC in the Women's Health Initiative cohort (N = 14,651). Cox proportional hazards regression models stratified by exposure-risk periods (0-1, >1-3, >3-5, >5-7, and >7-10 years) from ORC diagnosis and time-varying exposure (diabetes) analyses were performed.
resultsAmong the ORC survivors, a total of 1.3% developed diabetes within ≤1 year of follow-up and 2.5%, 2.3%, 2.3%, and 3.6% at 1-3, 3-5, 5-7, and 7-10 years of follow-up, respectively, after an ORC diagnosis. The median survival for those diagnosed with diabetes within 1-year of cancer diagnosis and those with no diabetes diagnosis in that time frame was 8.8 [95% confidence interval (CI), 7.0-14.5) years and 16.6 (95% CI, 16.1-17.0) years, respectively. New-onset compared with no diabetes as a time-varying exposure was associated with higher risk of all-cause (HR, 1.27; 95% CI, 1.16-1.40) and cancer-specific (HR, 1.17; 95% CI, 0.99-1.38) mortality. When stratified by exposure-risk periods, incident diabetes in ≤1 year of follow-up was associated with higher all-cause (HR, 1.76; 95% CI, 1.40-2.20) and cancer-specific (HR0-1, 1.82; 95% CI, 1.28-2.57) mortality, compared with no diabetes diagnosis.
conclusionsIncident diabetes was associated with worse cancer-specific and all-cause survival, particularly in the year after cancer diagnosis. IMPACT: These findings draw attention to the importance of diabetes prevention efforts among cancer survivors to improve survival outcomes.
Indexed as
Diabetes MellitusNeoplasmsFemaleHumansObesityProportional Hazards ModelsRisk FactorsWomen's Health
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
New-Onset Diabetes after an Obesity-Related Cancer Diagnosis and Survival Outcomes in the Women's Health Initiative. · full record | OpenQuestion